Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases by pioneering a small molecule, targeted approach to R&D. The company's proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to address the root cause of genetically defined rare diseases. Fulcrum's lead clinical programs are losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for sickle cell disease. Their approach aims to deliver a new generation of therapies that fundamentally alter the course of these debilitating conditions.
The Cambridge headquarters serves as the company's primary center for research and development, clinical operations, corporate strategy, and administrative functions.
Located in the heart of Kendall Square, the facility benefits from proximity to world-class academic institutions, research organizations, and a dense cluster of biotech and pharmaceutical companies, fostering a collaborative and innovative environment. The space likely includes state-of-the-art laboratories and modern office layouts.
Fulcrum Therapeutics cultivates a science-driven, patient-centric, and collaborative work culture. Employees are typically highly motivated by the mission to address unmet needs in rare diseases, with an emphasis on teamwork, scientific rigor, and innovation.
The headquarters' location in Cambridge is critical for attracting top scientific talent, facilitating collaborations with leading researchers and institutions, and staying at the forefront of biotechnological advancements.
While Fulcrum Therapeutics is headquartered in the United States, its operations, particularly clinical trials for its rare disease therapies, often involve international sites to ensure diverse patient recruitment and global reach. The company's research aims to address diseases affecting patients worldwide, and its business development and potential commercialization strategies may include global partnerships and markets.
26 Landsdowne Street
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Fulcrum Therapeutics' leadership includes:
Fulcrum Therapeutics has been backed by several prominent investors over the years, including:
Fulcrum Therapeutics has undergone significant leadership renewal over the past 12 months (approx. May 2023 - May 2024), with key appointments including a new CEO, CFO, CMO, CPO, and CLO, aimed at guiding the company's clinical programs and strategic objectives. There was also a CEO transition and a departure of the President of R&D.
Discover the tools Fulcrum Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Fulcrum Therapeutics commonly uses the email format of the first initial followed by the last name. For example, if an employee's name is Jane Doe, her email address would likely be jdoe@fulcrumtx.com. This is a standard convention for many companies in the biopharmaceutical industry.
[first_initial][last]@fulcrumtx.com
Format
jdoe@fulcrumtx.com
Example
80%
Success rate
Business Wire • May 15, 2024
Fulcrum Therapeutics announced that the Compensation Committee of Fulcrum's Board of Directors approved inducement stock options to purchase an aggregate of 260,000 shares of common stock to three new employees, granted as an inducement material to the new employees entering into employment with Fulcrum....more
Business Wire • May 9, 2024
Fulcrum Therapeutics reported its financial results for Q1 2024, highlighting progress in its clinical programs for FSHD and sickle cell disease, including enrollment updates for REACH Phase 1b trial of FTX-6058 and plans for losmapimod....more
Business Wire • May 7, 2024
Fulcrum Therapeutics announced that its President and CEO, Alex C. Sapir, would present at the Citizens JMP Life Sciences Conference on May 13, 2024, providing an overview of the company's progress and outlook....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Fulcrum Therapeutics, are just a search away.